Desensitization protocols for crossing human leukocyte antigen and ABO incompatible barriers

Current Opinion in Organ Transplantation

Volumn 12, Issue 4, 2007, Pages 371-378

  Jordan, Stanley C ^a   Locke, Jayme E ^b   Montgomery, Robert A ^b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Ross Research Building ^*  (United States)

Author keywords

ABO incompatible; Desensitization; Donor specific antibody; Positive crossmatch

Indexed keywords

DACLIZUMAB; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID; TACROLIMUS;

ADJUVANT THERAPY; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DESENSITIZATION; DIALYSIS; DONOR SELECTION; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; GRAFT SURVIVAL; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; NONHUMAN; ORGAN DONOR; OUTCOME ASSESSMENT; PLASMAPHERESIS; REVIEW; SPLENECTOMY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 34447505988     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282703903     Document Type: Review

References (58)

1. Evans RW, Manninen DL, Garrison LPJ, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312:553-559.
2. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270:1339-1343.
3. Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation - a prospective study. Transplantation 1992; 54:656-660.
4. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with preexisting humoral antibodies against donor cells. Lancet 1966; 2:662-665.
5. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
6. Williams GM, Hume DM, Hudson RPJ, et al. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968; 279:611-618.
7. Starzl TE, Marchioro TL, Holmes JH, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964; 55:195-200.
8. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3:1017-1023.
9. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75:971-977.
10. Montgomery RA, Cooper M, Kraus E, et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transpl 2003; 199-213.
11. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887-895.
12. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70:1531-1536.
13. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004; 17:1-8.
14. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2:758-760.
15. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56:335-337.
16. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631-636.
17. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57:553-562.
18. Alexandre GP, Squifflet JP, De Bruyere M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19:4538-4542.
19. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998; 65:224-228.
20. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4:1089-1096.
21. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4:1315-1322.
22. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76:730-731.
23. Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34:1614-1616.
24. Alexandre GP, Squifflet JP, De Bruyere M, et al. Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proc 1985; 17:138-143.
25. Breimer ME, Samuelsson BE. The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation 1986; 42:88-91.
26. Clausen H, Levery SB, Nudelman E, et al. Repetitive A epitope (type 3 chain A) defined by blood group A1-specific monoclonal antibody TH-1: chemical basis of qualitative A1 and A2 distinction. Proc Natl Acad Sci U S A 1985; 82:1199-1203.
27. Economidou J, Hughes-Jones NC, Gardner B. Quantitative measurements concerning A and B antigen sites. Vox Sang 1967; 12:321-328.
28. Nelson PW, Helling TS, Pierce GE, et al. Successful transplantation of blood group A2 kidneys into non-A recipients. Transplantation 1988; 45:316-319.
29. Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4:561-568.
30. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003; 3:653-664.
31. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66:800-805.
32. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256-3262.
33. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
34. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-486.
35. Lutz HU, Stammler P, Bianchi V, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004; 103:465-472.
36. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96:2404-2412.
37. Toyoda M, Pao A, Petrosian A, Jordan SC. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003; 3:156-166.
38. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006; 203:789-797. This paper establishes the significance of specific IgG subclasses and their cognate Fc gamma receptors in renal disease.
39. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115:3440-3450.
40. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101:758-765.
41. Abe J, Jibiki T, Noma S, et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005; 174:5837-5845.
42. Gill V, Doig C, Knight D, et al. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005; 112:2031-2039.
43. Turhan A, Jenab P, Bruhns P, et al. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004; 103:2397-2400.
44. Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26:67-78. These results suggest that the ability to inhibit macrophage responses to interferon gamma may be a property of intravenous immunoglobulin.
45. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71:53-58.
46. De Marco T, Damon LE, Colombe B, et al. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997; 16:360-365.
47. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and antilymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72:419-422.
48. Jordan SC, Pescovitz M. Presensitization: the problem and its management. Clinical Journal of the American Society of Nephrology 2006; 1:421-432. This paper describes the addition of anti-CD20 therapy to high-dose intravenous immunoglobulin desensitization regimen allowing for more rapid desensitization with reduction in costs and improved outcomes.
49. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6:459-466. This paper reviews the mechanism of action of intravenous immunoglobulin and its role in the highly sensitized end-stage renal disease patient.
50. Vo A, Cam V, Toyoda M, et al. Safety and adverse event profiles of IVIG products used for immunomodulation: a single center experience. Clinical Journal of the American Society of Nephrology 2006; 1:844-852. This paper reviews the complications associated with IVIG infusions in patients with normal renal function and those on dialysis.
51. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8:535-542.
52. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6:346-351. This paper compares high-dose IVIG and plasmapheresis and the authors conclude that plasmapheresis leads to more reproducible desensitization and lower humoral rejection.
53. Kaplan B, Gangemi A, Thielke J, et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83:99-100. This paper suggests a role for splenectomy in treating antibody-mediated rejection refractory to standard therapy.
54. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842-846. This paper suggests that emergent splenectomy followed by plasmapheresis/IVIG is an effective treatment for reversing severe antibody mediated rejection.
55. Gentry SE, Segev DL, Montgomery RA. A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 2005; 5:1914-1921.
56. Segev DL, Gentry SE, Warren DS, et al. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005; 293:1883-1890.
57. Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005; 294:1655-1663.
58. Locke JE, Segev DL, Gentry SE, et al. Combining kidney paired donation, desensitization, and nondirected donors to transplant multiple highly sensitized patients [abstract]. Am J Transplant 2006; 6 (Suppl 2):808.